Molecular classification of prostate cancer using curated expression signatures

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 52, 2011, Pages 21276-21281

  Markert, Elke K ^a   Mizuno, Hideaki ^b,c   Vazquez, Alexei ^a,d,e   Levine, Arnold J ^a,d,e  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b Chugai Pharmaceutical   (Japan)

^c KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Prognostic value; Stem ness; Transcriptional profile

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENZYME INACTIVATION; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION;

BAYES THEOREM; EMBRYONIC STEM CELLS; GENE EXPRESSION PROFILING; HUMANS; MALE; MICROARRAY ANALYSIS; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SWEDEN; TUMOR SUPPRESSOR PROTEIN P53; WATCHFUL WAITING;

EID: 84855484465     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117029108     Document Type: Article

References (35)

1. Perou CM, et al. (2000) Molecular portraits of human breast tumours. Nature 406:747-752.
2. Weigelt B, et al. (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65:9155-9158.
3. Ben-Porath I, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499-507.
4. Mizuno H, Spike BT, Wahl GM, Levine AJ (2010) Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 107:22745-22750.
5. Woo HG, et al. (2010) Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 140:1063-1070.
6. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
7. Kawamura T, et al. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460:1140-1144.
8. Marión RM, et al. (2009) A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460:1149-1153.
9. Hanna J, et al. (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462:595-601.
10. Hong H, et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460:1132-1135.
11. Li H, et al. (2009) The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460:1136-1139.
12. American Cancer Society (2009) Cancer Facts & Figures 2009 (American Cancer Society, Atlanta).
13. Wang SY, et al. (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480-1485.
14. Sircar K, et al. (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218:505-513.
15. Clark J, et al. (2008) Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27:1993-2003.
16. Mosquera JM, et al. (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14:3380-3385.
17. Albadine R, et al. (2009) TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 22:1415-1422.
18. Carver BS, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41:619-624.
19. Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347-8351.
20. Klezovitch O, et al. (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105:2105-2110.
21. Tomlins SA, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-188.
22. Agell L, et al. (2008) KLF6 and TP53 mutations are a rare event in prostate cancer: Distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 21:1470-1478.
23. Schlomm T, et al. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21:1371-1378.
24. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22.
25. Jenkins RB, Qian J, Lieber MM, Bostwick DG (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531.
26. Gurel B, et al. (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21:1156-1167.
27. Sboner A, et al. (2010) Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 3:8.
28. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273.
29. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550.
30. Attard G, et al.; Transatlantic Prostate Group (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27:253-263.
31. Fine SW, et al. (2010) TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 23:1325-1333.
32. Mason TE, et al. (2010) Association of CD14 variant with prostate cancer in African American men. Prostate 70:262-269.
33. American Cancer Society (2005) Cancer Facts & Figures for African Americans 2005-2006 (American Cancer Society, Atlanta), pp 1-28.
34. Kim J, et al. (2011) A mouse model of heterozygous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene, 10.1038/onc.2011.236.
35. Clegg NJ, et al. (2011) MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE 6(3):1-14.